Menu Search
Equities

Vivoryon Therapeutics NV

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0R3M:LSE

Vivoryon Therapeutics NV

Actions
  • Price (EUR)1.44
  • Today's Change-0.002 / -0.14%
  • Shares traded20.00
  • 1 Year change-26.18%
  • Beta1.4254
Data delayed at least 20 minutes, as of Feb 06 2026 08:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company focused on discovering, developing, and potentially commercializing small molecule-based medicines that modulate the activity and stability of pathologically altered proteins. The Company has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. It focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-12.48m
  • Incorporated--
  • Employees14.00
  • Location
    Vivoryon Therapeutics NVWeinbergweg 22HALLE 06120GermanyDEU
  • Phone+49 3 455559900
  • Fax+49 3 455559901
  • Websitehttps://www.vivoryon.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.